<SEC-DOCUMENT>0001161697-19-000360.txt : 20190904
<SEC-HEADER>0001161697-19-000360.hdr.sgml : 20190904
<ACCEPTANCE-DATETIME>20190904101334
ACCESSION NUMBER:		0001161697-19-000360
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190904
DATE AS OF CHANGE:		20190904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229498
		FILM NUMBER:		191073491

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prospectus_424b3-sup7.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT NO. 7 TO 424(B)(3)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:7.5in">
<BR>

<P style="margin:0px; font-size:12pt" align=right>Filed Pursuant to Rule 424(b)(3) </P>
<P style="margin:0px; font-size:12pt" align=right>Registration No. 333-229498</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>PROSPECTUS SUPPLEMENT NO. 7</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>(to Prospectus dated March 8, 2019)</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>REPRO MED SYSTEMS, INC.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>11,101,697 shares of common stock</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">This prospectus supplement No. 7 supplements and amends the prospectus dated March 8, 2019, as supplemented
by prospectus supplement No. 1, dated April 29, 2019, as further supplemented by prospectus supplement No. 2, dated May 7, 2019,
prospectus supplement No. 3, dated May 8, 2019, prospectus supplement No. 4, dated June 27, 2019 and prospectus supplement No.
5, dated July 2, 2019 and prospectus supplement No. 6, dated August 7, 2019 (collectively, the &ldquo;Prospectus&rdquo;), which forms a part of our Registration Statement on Form S-1
(Registration No. 333-229498). This prospectus supplement is being filed to update and supplement the information in the Prospectus with
information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 4, 2019
(the &ldquo;Current Report&rdquo;). Accordingly, we have attached the Current Report to this prospectus supplement.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">The Prospectus and this prospectus supplement relate solely to 11,101,697 shares of REPRO MED SYSTEMS, INC. common stock, par value $0.01 per share, which we refer to as our common stock, which may be offered for sale from time to time by the stockholders named under the heading &ldquo;Selling Stockholders&rdquo; in the Prospectus.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">This prospectus supplement should be read in conjunction with the Prospectus, including any supplements or amendments thereto. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. &nbsp;This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">Our common stock is currently listed on the OTCQX under the symbol &ldquo;REPR.&rdquo; The closing price of
our common stock as reported on the OTCQX on August 30, 2019, was $3.50.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify"><B>Investing in our common stock involves risks, and you should not invest unless you can afford to lose your entire investment. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 5 of the Prospectus. </B></P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center><B>The date of this prospectus supplement is September 4, 2019.</B></P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>August 30, 2019</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">common stock, $0.01 par value </P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">REPR</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">OTCQX</P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">As previously reported in the reports filed under the Securities Exchange Act of 1934, as amended by Repro
Med Systems, Inc. d/b/a RMS Medical Products (the &ldquo;Company&rdquo;), on November 7, 2017, EMED Technologies Corporation (&ldquo;EMED&rdquo;)
filed a case in the United States District Court for the Eastern District of Texas claiming patent infringement of U.S. Patent
9,808,576 (&ldquo;&lsquo;576 Patent&rdquo;) by the Company&rsquo;s needle sets and seeking unspecified monetary damages (the &ldquo;&rsquo;576
Case&rdquo;). The &lsquo;576 Case was later transferred to the United States District Court for the Southern District of New York
and is one of several pending between the Company and EMED.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">The Company is filling this Current Report on Form 8-K to report that, on August 30, 2019, the United States
District Court for the Southern District of New York issued a decision with respect to the &lsquo;576 Case granting the Company&rsquo;s
motion for summary judgement of non-infringement against the &lsquo;576 Patent and dismissed the case with prejudice.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On September 3, 2019, the Company issued a press release announcing the events set forth in this Current Report
on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD>Press release dated September 3, 2019</TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:48; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>September 4, 2019</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Karen Fisher</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Karen Fisher<BR>
Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 3 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0px" align=center><B>Exhibit 99.1</B></P>

<P style="margin:0px">&nbsp;</P>

<P style="margin:0px"><img src="rms_logo.jpg"></P>

<P style="margin:0px">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>FOR IMMEDIATE RELEASE</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RMS MEDICAL PRODUCTS RECEIVES ANOTHER FAVORABLE COURT RULING</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CHESTER, NY &ndash; September 3, 2019 -
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (&ldquo;RMS
Medical&rdquo; or &ldquo;the Company&rdquo;) today announced that on August 30, 2019 the United States District Court for the Southern
District of New York (Case No. 1:18-cv-05880-LGS) issued a decision granting RMS Medical&rsquo;s motion for summary judgement of
non-infringement against EMED Technologies (&ldquo;EMED&rdquo;) U.S. Patent 9,808,576 (&ldquo;&lsquo;576 Patent&rdquo;) and dismissed
the case with prejudice.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 7, 2017, EMED filed this case in the United States District Court for the Eastern District of
Texas claiming patent infringement of the &lsquo;576 Patent by the Company&rsquo;s needle sets and seeking unspecified monetary
damages. The case was later transferred to the United States District Court for the Southern District of New York and is one of
several pending between RMS Medical and EMED.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;We are very pleased with the decision of U.S. District Court for the Southern District of New York,
which confirms our belief that EMED&rsquo;s infringement claim was without merit,&rdquo; said Don Pettigrew, President and CEO
of RMS Medical. &ldquo;This ruling is the second consecutive favorable judgement that we have received regarding our ongoing litigation
with EMED.&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2019, the United States District Judge for the Eastern
District of Texas dismissed with prejudice EMED&rsquo;s case on an earlier issued patent against RMS Medical and awarded court costs to RMS Medical. Subsequent to the Texas ruling, RMS
Medical authorized its legal counsel to pursue recovery of legal fees from EMED associated with the Texas case.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>About RMS Medical Products</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RMS Medical develops, manufactures and commercializes innovative and easy-to-use specialty infusion solutions
that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60<SUP>&reg;</SUP>
and FreedomEdge<SUP>&reg;</SUP> Syringe Infusion Drivers, RMS Precision Flow Rate Tubing<SUP>&trade;</SUP> and RMS HIgH-Flo Subcutaneous
Safety Needle Sets<SUP>&trade;</SUP>. These devices are used for infusions administered in the home and alternate care settings.
For more information about RMS Medical, please visit https://www.rmsmedicalproducts.com.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The statements contained herein include prospects, statements of future expectations and other forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management's current views
and assumptions and involve known and unknown risks and uncertainties, identified by words such as &ldquo;belief&rdquo;. Actual
results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Factors
that may cause actual results to differ materially from current expectations and other risks are discussed in RMS Medical&rsquo;s
filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, which filings are available
from the SEC and RMS Medical&rsquo;s website. RMS Medical undertakes no obligation to update any forward-looking statements.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Contacts:</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 179.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>The Equity Group Inc.</B></FONT></TD>
    <TD STYLE="width: 180.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Devin Sullivan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Kalle Ahl, CFA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Senior Vice President</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">212-836-9608</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">212-836-9614</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">mailto: dsullivan@equityny.com</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">kahl@equityny.com </FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>rms_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rms_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P *H# 2(  A$! Q$!_\0
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MQ/\ LJ_&Z:8.=Y8/!>_"GXP7&F619XV_X1OXA,VC9)^)'P]T6,ZO]7?M??\
M!QO\>/VA/"7A#X.?L/?"/QC\&/&OQ"TS2=%\6^*9!9_$KXP3>--=7['=_#WX
M!:#X6TJZ^T[[AA8Z-\0Y](?QYXA?4%7PQX%\ Z_8:?J]S\;BO WB'%X_ 5>$
M,SR;B;A/-5.OA>*XX_"X/!X#"4E&==YY1J5_;8*OAJ<I*<*-.HZE:C5I.C@:
ML94Z7H1XDPE.G...IU<%C:+4:F!E"=6K.H[+_9I4X.%:FY:*=[)/FD^75_T(
M_P#!1#_@L!^S!_P3[M9O#'B34#\6/C[/:076C_ +P'JMHOB*UMKV/S['6_B/
MXC>WU#2?AEX;N(O)EM9=8@OO%.MV\_VSPMX.\0V-IJESIWJ7_!.[_@H%X1_;
M\_9<F_:4M_!5U\'X/#_BSQ=X*\?^&O$?B.RUO3/"^L>#M/TK6]1U"T\8"QT"
M'5?#3>'M<TG5FU.]T30I;-I+^TN;,#3_ +7<_P 9WQ=_X(S?'WX$?L"_'O\
M;S_:[\6ZCX9^*5A/\+=1\*?!U]2C\7>-[[5OBM\<OAQX$UWQ?\>/'=]<ZOO\
M07&E>,=<U!?">BWVJZTFNS6&K>*?&%I>VNL^$+C]8O\ @D%X8\6>./\ @@C_
M ,%!O!/@*QO]3\<>+V_;4\,>$-,TI9)-5U3Q+KO[,_@[2]&TW2TA(E.I:A?W
M,%E8"%UE^USPF)T<!AZW$?AWX>8+@&./R+/*F>9Q@^.,BX4S?BJ$Z]#*(SS*
MI0IYE# 8626'J9;@:.*ABH8EU:E><\-4G5Q4XQE3,,)FN;5<T6'Q>'AA*-3
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M<(Q@^*AFN.Q5%5ZV?Y=@9U93DL)4PJA5H14Y*,*LI-N;T34DM5K+WG)'@/\
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?2V2N[1C=+W8JRCOI]J2LSJO?K?HGY+17OUTU\S__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
